Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.

The second quarter in South Korea was marked by the return of several assets by licensing partners, including Thea Open Innovation, which gave back rights to two ophthalmic programs in-licensed from OliX. Merck & Co. also cancelled a co-research deal with Artiva Biotherapeutics.